Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential sIPV and wIPV Vaccination in Infants
NCT07457060Phase 4Recruiting
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis, sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroprotection Rate of neutralizing antibodies against polioviruses and Frequency of adverse reactions. Started Nov 2025; status: recruiting.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT07457060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457060.